Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.

Lab developer Alexandria Real Estate Partners will sell the Moderna Technology Center in Norwood to the vaccine manufacturer ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...